AlphAIalphai — Financial news for AI agents
investing.comSEP 42 min read$TEVA

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

Original reporting
investing.com
Published Sep 4, 2026, 7:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$TEVA
Bullish
high confidence
Mentioned
$TEVA
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

The upgrade reflects improved financial metrics and a stronger pipeline, likely supporting a tighter credit spread.

02

Market read

Credit upgrade could prompt short‑term buying and influence sector credit spreads.

03

What to watch

Potential regulatory or pipeline setbacks could offset credit improvements.

Relevance 7/10Novelty 8/10Timing: Friday

Background

Teva has reduced gross debt from $29B in 2018 to $17B in 2025 and targets 2x net leverage by year‑end.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

S&P Global Ratings upgraded Teva to BBB- from BB+, citing deleveraging and pipeline strength.

Expected impact

Potential short-term price upside as investors reprice credit risk.

Evidence & confidence

Upgrade is a fresh, material credit event for a mid‑cap pharma, likely to attract credit‑focused buying.

Market effects

Sector

May lift sentiment for the broader pharma sector as credit conditions improve.

Regional

Limited to markets where Teva has significant exposure, primarily US and Israel.

Global

Modest; credit rating agencies' actions are watched globally but impact is company‑specific.

Counterpoint

What could challenge this read

If debt reduction stalls, the upgrade could be premature and price may correct.

Key entities

  • Rating Agency
    S&P Global Ratings

    Provided the credit upgrade and outlook.

  • Company
    Teva Pharmaceutical Industries Ltd.

    Subject of the rating upgrade.

Read at source← All news

Related articles

SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

Teva Pharmaceutical (TEVA) reported positive Phase 2a trial results for TEV-408, an anti-IL-15 monoclonal antibody, in celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage. TEV-408 also reduced inflammation and improved patient-reported outcomes. The company plans to present further data and host an investor call. TEVA stock closed at $36.19, up 0.39%, and is up 0.77% in pre-market trading.

rttnews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

Teva Pharmaceutical (TEVA) reported positive topline results from a Phase 2a study of TEV 408, an anti-interleukin-15 monoclonal antibody, for treating celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage compared to placebo. The company plans to present further data at a future scientific meeting. TEVA shares rose 2.96% in pre-market trading.

rttnews.com1 min